NCT Number: NCT06136624
Phase: PHASE3
Trial Summary: This is a phase 3, randomized, open-label study of MK-5684 compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Merck Sharp & Dohme LLC
Acronym:
Study of MK-5684 Versus Alternative NHA in mCRPC (MK-5684-003)
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives